Flash Electroretinography Parameters and Parkinson's Disease.


Journal

Journal of Parkinson's disease
ISSN: 1877-718X
Titre abrégé: J Parkinsons Dis
Pays: Netherlands
ID NLM: 101567362

Informations de publication

Date de publication:
2021
Historique:
pubmed: 20 10 2020
medline: 16 11 2021
entrez: 19 10 2020
Statut: ppublish

Résumé

Parkinson's disease (PD) is known to affect retinal structure and activity. As such, retinal evaluations may be used to develop objective and possibly early PD diagnostic tools. The aim of this study was to investigate the effects of Parkinson's disease (PD) manifestation and treatment on retinal activity. Data were collected on 21 participants diagnosed with PD, including the number of medications taken, clinical scales and flash electroretinography (fERG) measurements, under light-adapted and dark-adapted conditions. The fERG parameters measured included a-wave and b-wave amplitude and implicit time (i.e., latency). First, we investigated correlations between symptom measure scores and the fERG parameters. Next, we divided participants into two groups based on their antiparkinsonian medication load and analyzed differences between these groups' fERG parameters. fERG parameters were strongly correlated with a number of clinical variables, including motor and non-motor symptoms and age at PD onset. Photoreceptor cell implicit time was longer among participants taking one or less antiparkinsonian medication as compared to those taking two or more. However, overall there was not strong evidence of a relationship between the number of antiparkinsonian medications taken and the fERG parameters. Findings suggest that fERG may be a useful, non-intrusive measure of retinal, and, perhaps overall CNS function, in PD. However, additional studies in larger samples are needed to clarify this association.

Sections du résumé

BACKGROUND
Parkinson's disease (PD) is known to affect retinal structure and activity. As such, retinal evaluations may be used to develop objective and possibly early PD diagnostic tools.
OBJECTIVE
The aim of this study was to investigate the effects of Parkinson's disease (PD) manifestation and treatment on retinal activity.
METHODS
Data were collected on 21 participants diagnosed with PD, including the number of medications taken, clinical scales and flash electroretinography (fERG) measurements, under light-adapted and dark-adapted conditions. The fERG parameters measured included a-wave and b-wave amplitude and implicit time (i.e., latency). First, we investigated correlations between symptom measure scores and the fERG parameters. Next, we divided participants into two groups based on their antiparkinsonian medication load and analyzed differences between these groups' fERG parameters.
RESULTS
fERG parameters were strongly correlated with a number of clinical variables, including motor and non-motor symptoms and age at PD onset. Photoreceptor cell implicit time was longer among participants taking one or less antiparkinsonian medication as compared to those taking two or more. However, overall there was not strong evidence of a relationship between the number of antiparkinsonian medications taken and the fERG parameters.
CONCLUSION
Findings suggest that fERG may be a useful, non-intrusive measure of retinal, and, perhaps overall CNS function, in PD. However, additional studies in larger samples are needed to clarify this association.

Identifiants

pubmed: 33074189
pii: JPD191830
doi: 10.3233/JPD-191830
doi:

Substances chimiques

Antiparkinson Agents 0
Biomarkers 0

Types de publication

Journal Article Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

251-259

Auteurs

Roni Netser (R)

Shalvata Mental Health Center, Hod Hasharon, Israel.

Docia L Demmin (DL)

Department of Psychology, Rutgers University, Piscataway, NJ, USA.

Roseanne Dobkin (R)

Department of Psychiatry, Rutgers - Robert Wood Johnson Medical School, Piscataway, NJ, USA.

Ariel Goldstein (A)

Princeton Neuroscience Institute, Princeton University, Princeton, NJ, USA.

Matthew Roché (M)

Rutgers University - University Behavioral Health Care, Piscataway, NJ, USA.

Steven M Silverstein (SM)

Department of Psychiatry, Rutgers - Robert Wood Johnson Medical School, Piscataway, NJ, USA.
Rutgers University - University Behavioral Health Care, Piscataway, NJ, USA.
Department of Ophthalmology, Rutgers - Robert Wood Johnson Medical School, Piscataway, NJ, USA.
Departments of Psychiatry, Neuroscience, and Ophthalmology, University of Rochester Medical Center, Rochester, NY, USA.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH